

Applicants: B. Jack Longley
Serial No.: Not Yet Known
Filed : December 29, 1999
Page 2

with an antibody, peptide, or nonpeptide chemical.--

- 15. (Amended) The method of [any one of claims 1-9] claim 1, which comprises inhibiting kit dimerization with an antibody, peptide, or nonpeptide chemical.--
- 16. (Amended) The method of [any one of claims 1-9] claim 1, wherein downstream signaling of the kit activation pathway is inhibited by blocking substrate association with kit kinase domain.--
- 17. (Amended) The method of [any one of claims 1-9] claim 1, wherein downstream signaling of the kit activation pathway is inhibited by blocking enzymatic function in the downstream signaling pathway.--
- 18. (Amended) The method of [any one of claims 1-9] claim 1, wherein downstream signaling of the kit activation pathway is inhibited by blocking binding of molecules in the downstream signaling pathway.--
- 19. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound is an antibody or portion thereof.--
- 23. (Amended) The method of claim [22] 19, wherein the [anti-kit] antibody is ACK2.--
- 24. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound comprises a Fab

Sub
B2
A
concl'd

Applicants: B. Jack Longley
Serial No.: Not Yet Known
Filed : December 29, 1999
Page 3

~~fragment of an anti-kit antibody.--~~

Cond
--25. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound comprises the variable domain of an anti-kit antibody.--

--26. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound comprises one or more CDR portions of an anti-kit antibody.--

Subt B3
--28. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound comprises a peptide, peptidomimetic, a nucleic acid, or an organic compound with a molecular weight less than 500 Daltons.--

3
--29. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound is sSCF, sKIT ligand or a fragment thereof.--

--30. (Amended) The method of [any one of claims 1-9] claim 1, wherein the compound is sKIT or a fragment thereof.--

--31. (Amended) The method of [any one of claims 1-9] claim 1, wherein the subject is a mammal.--

Subt B4
--33. (Amended) The method of [any one of claims 1-9] claim 1, wherein the administration is intralesional, intraperitoneal, intramuscular, subcutaneous, intravenous, liposome mediated delivery, transmucosal, intestinal, topical, nasal, oral, anal, ocular or otic delivery.